Tag Archives: Defence Therapeutics

Montreal, Quebec–(Newsfile Corp. – April 24, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company“), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the Company approved the grant of 200,000 incentive restricted stock units (“RSUs“) to …

Montreal, Quebec–(Newsfile Corp. – March 20, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company“), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a total of 800,000 Common Share purchase warrants (the “Warrants“) originally issued …

Montreal, Quebec–(Newsfile Corp. – March 9, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), (“Defence” or the “Company“), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private placement (the “Private Placement“) of 17,445,455 units (the “Units“) at a price of …

Montreal, Quebec–(Newsfile Corp. – March 2, 2026) – Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major international industry events taking place in March …

Montreal, Quebec–(Newsfile Corp. – February 27, 2026) – Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private placement (the “Private Placement“) of up to 20,000,000 units (the “Units“) at a …